Ivy-Joan Madu, MD
Endocrinology, Diabetes & Metabolism · Orange, CANPI 1710988662
Payments from drug & device makers
Across 479 payments — averaging $4317.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$1.1M
- AbbVie$816K
- AstraZeneca$61K
- Boehringer Ingelheim Pharma GmbH & Co.kg$18K
- Novo Nordisk AS$16K
- Boehringer Ingelheim$14K
- plus $15K from 30 others
Across 18 payments — averaging $1070.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$17K
- AbbVie$2K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 28 | $1,127,993 |
| AbbVie | 82 | $815,510 |
| AstraZeneca(2 entities) | 20 | $60,541 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 5 | $18,362 |
| Novo Nordisk AS | 108 | $16,432 |
| Boehringer Ingelheim | 11 | $14,449 |
| Corcept Therapeutics | 10 | $4,020 |
| Amgen(2 entities) | 39 | $3,783 |
| Boehringer Ingelheim International GmbH | 12 | $1,380 |
| Sanofi US Services Inc. | 2 | $1,322 |
| Merck | 6 | $1,202 |
| Dexcom, Inc. | 43 | $611 |
| Lilly USA, LLC | 21 | $408 |
| Novo Nordisk | 14 | $319 |
| Sanofi-aventis U.S. LLC | 17 | $305 |
| Abbott | 15 | $258 |
| Radius Health, Inc. | 8 | $158 |
| Mannkind Corporation | 6 | $135 |
| Pfizer | 4 | $89 |
| Sequel Med Tech, LLC | 3 | $83 |
| Ipsen Biopharmaceuticals, Inc | 2 | $73 |
| Johnson & Johnson | 2 | $46 |
| Xeris Pharmaceuticals, Inc. | 2 | $44 |
| Shire North American Group Inc | 2 | $43 |
| Amarin Pharma, Inc. | 2 | $42 |
| Antares Pharma, Inc. | 2 | $37 |
| Insulet Corporation | 2 | $32 |
| BD | 1 | $31 |
| Neurocrine Biosciences, Inc. | 1 | $28 |
| Recordati_rare_diseases_inc. | 1 | $27 |
| Tandem Diabetes Care, Inc. | 1 | $26 |
| Rhythm Pharmaceuticals, Inc. | 1 | $26 |
| Ascendis Pharma Endocrinology Inc | 1 | $24 |
| BETA Bionics, Inc. | 3 | $22 |
| Chiesi USA, Inc. | 1 | $17 |
| Medtronic | 1 | $16 |
How this compares
$2,067,894 in reported general payments places this provider in the 95th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other endocrinology, diabetes & metabolism in Orange
- Jerrold OlefskySan Diego$26.5M
- Mark ChristiansenWalnut Creek$22.9M
- Timothy BaileyEscondido$22.3M
- Stanley HsiaLos Angeles$19.8M
- Juan FriasSan Diego$14.1M
- Paul NorwoodFresno$6.2M
- Athena Philis-Tsimikasla Jolla$6M
- David AhnNewport Beach$5.8M
- Shlomo MelmedLos Angeles$3.3M
- Leila ChaychiSan Carlos$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.